Systemic Mycosis

Aquilar, E. Solano; Negroni, Ricardo; Meinhof, W.; Padilha-Gonçalves, Antar; Pappagianis, Demosthenes; Iwata, Kimiko; Mendoza, A. Gonzalez; Graybill, John R.

doi:10.1007/978-3-642-83360-1_48

Cited by 1 publication

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from bacteria and viruses, people can also become infected by fungi and the resulting diseases are known as mycoses [ 1 ]. For example, the thrush fungus Candida albicans can infect the mouth/throat area [ 2 ] but can also cause a systemic mycosis spreading throughout the entire body [ 3 ]. Mycoses of the skin, hair, fingernails and toenails or mucous membranes are also common [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Allicin as a Volatile or Nebulisable Antimycotic for the Treatment of Pulmonary Mycoses: In Vitro Studies Using a Lung Flow Test Rig

Schier

Foerster

Heupel

et al. 2022

IJMS

View full text Add to dashboard Cite

Fungal infections of the lung are an increasing problem worldwide and the search for novel therapeutic agents is a current challenge due to emerging resistance to current antimycotics. The volatile defence substance allicin is formed naturally by freshly injured garlic plants and exhibits broad antimicrobial potency. Chemically synthesised allicin was active against selected fungi upon direct contact and via the gas phase at comparable concentrations to the pharmaceutically used antimycotic amphotericin B. We investigated the suppression of fungal growth by allicin vapour and aerosols in vitro in a test rig at air flow conditions mimicking the human lung. The effect of allicin via the gas phase was enhanced by ethanol. Our results suggest that allicin is a potential candidate for development for use in antifungal therapy for lung and upper respiratory tract infections.

show abstract

Section: Introductionmentioning

confidence: 99%